On June 13, 2024, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, with a significant turnout of approximately 82.93% of Class A and Class B common stockholders. During the meeting, shareholders voted on several key proposals. The first proposal involved the election of nine director nominees, with two designated for election by Class B common stockholders and seven by the combined vote of Class A and Class B stockholders. All nine nominees were successfully elected to the Board of Directors. The second proposal was the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which was approved by the shareholders. The third proposal, an advisory vote on executive compensation for the Company's named executive officers, also received approval. The meeting concluded with the required signatures, including that of Mark Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc.

On June 13, 2024, Ginkgo Bioworks Holdings, Inc. conducted its annual meeting of shareholders, with a significant turnout of approximately 82.93% of Class A and Class B common stockholders. During the meeting, shareholders voted on several key proposals. The first proposal involved the election of nine director nominees, with two designated for election by Class B common stockholders and seven by the combined vote of Class A and Class B stockholders. All nine nominees were successfully elected to the Board of Directors. The second proposal was the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, which was approved by the shareholders. The third proposal, an advisory vote on executive compensation for the Company's named executive officers, also received approval. The meeting concluded with the required signatures, including that of Mark Dmytruk, the Chief Financial Officer of Ginkgo Bioworks Holdings, Inc.